Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction

 

 Buy Article Permissions and Reprints

Summary

While acute myocardial infarction (MI) is associated with impaired clopidogrel responsiveness, systematic evaluation is lacking due to the inability of functional aggregation-based assays to analyse clopidogrel responsiveness in the presence of glycoprotein IIb/IIIa inhibitors. Using the P2Y₁₂-specific, non-aggregation-based platelet-reactivity-index (PRI) we assessed clopidogrel responsiveness in patients with acute MI. Clopidogrel responsiveness was determined 24 hours (h) after loading with 600 mg clopidogrel in 54 patients with acute MI admitted for coronary intervention. A PRI > 50% was considered as suboptimal inhibition. Overall response in MI patients was suboptimal with a median PRI of 58%. Diabetes, low high-density lipoprotein and pre-hospital clopidogrel loading were associated with impaired clopidogrel responsiveness. Patients loaded at first medical contact had a significantly weaker platelet inhibition by clopidogrel after 24 h (PRI 63%) compared to those loaded peri-interventionally (PRI 54%, p=0.014). Clinical outcome was assessed as a combination of cardiac death, non-fatal MI, stent thrombosis, ischaemic stroke, and urgent target vessel revascularisation after 12 months. The pre-selected cut-off of PRI ≤ 50% yielded a sensitivity of 87% at a specificity of 26%, whereas a PRI ≤ 57% determined by receiver-operating characteristics (ROC)-analysis yielded a sensitivity of 80% at a specificity of 56% (event rate: PRI ≤ 57%: 12.0%; PRI > 57%: 41.4%, p=0.0136). In conclusion, PRI detects clopidogrel responsiveness in acute MI patients requiring glycoprotein IIb/IIIa antagonism; and impaired clopidogrel responsiveness predisposes to clinical events. Pre-hospital clopidogrel loading was associated with impaired response and more adverse events challenging the concept of earliest oral clopidogrel loading in MI patients.

• References

• 1 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
  CrossrefPubMedGoogle Scholar
• 3 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
  CrossrefPubMedGoogle Scholar
• 4 Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004; 109: 3064-3067.
  CrossrefPubMedGoogle Scholar
• 5 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
  CrossrefPubMedGoogle Scholar
• 7 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
  CrossrefPubMedGoogle Scholar
• 8 Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-1987.
  CrossrefPubMedGoogle Scholar
• 9 Schäfer A, Bauersachs J, Eigenthaler M. Clopidogrel - Klinischer Einsatz und mögliche Therapieprobleme. Herz 2008; 33: 280-286.
  CrossrefPubMedGoogle Scholar
• 10 Schäfer A, Weinberger S, Flierl U. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008; 100: 618-625.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Silber S, Albertsson P, Aviles FF. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
  CrossrefPubMedGoogle Scholar
• 12 Smith SC, Jr. Feldman TE, Hirshfeld JW. Jr. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-175.
  CrossrefPubMedGoogle Scholar
• 13 Van de WF, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
  CrossrefPubMedGoogle Scholar
• 14 Antman EM, Hand M, Armstrong PW. et al. 2007 Focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 2008; 117: 296-329.
  CrossrefPubMedGoogle Scholar
• 15 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
  CrossrefPubMedGoogle Scholar
• 16 Alexander D, Mann N, Ou FS. et al. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Am J Cardiol 2008; 102: 1335-1340.
  CrossrefPubMedGoogle Scholar
• 17 Osmancik P, Jirmar R, Hulikova K. et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166.
  CrossrefPubMedGoogle Scholar
• 18 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
  CrossrefPubMedGoogle Scholar
• 20 Barragan P, Bouvier J-L, Roquebert P-O. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phoshorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
  CrossrefPubMedGoogle Scholar
• 21 Bonello L, Paganelli F, Arpin-Bornet M. et al. Vasodilator-stimulated phospho- protein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
  CrossrefPubMedGoogle Scholar
• 22 Blindt R, Stellbrink K, De Taeye A. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in nonST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
  CrossrefPubMedGoogle Scholar
• 25 Thygesen K, Alpert JS, White HD. et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
  CrossrefPubMedGoogle Scholar
• 26 Gurbel PA, Becker RC, Mann KG. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
  CrossrefPubMedGoogle Scholar
• 27 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
  CrossrefPubMedGoogle Scholar
• 28 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007; 115: 708-716.
  CrossrefPubMedGoogle Scholar
• 29 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
  CrossrefPubMedGoogle Scholar
• 30 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007; 115: 708-716.
  CrossrefPubMedGoogle Scholar
• 31 Hodgson J, Stone GW, Lincoff AM. et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent task force. Cath Cardiovasc Interv 2007; 69: 327-333.
  CrossrefPubMedGoogle Scholar
• 32 Wiviott SD, Braunwald E, Angiolillo DJ. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
  CrossrefPubMedGoogle Scholar
• 33 Shattil SJ, Anaya-Galindo R, Bennett J. et al. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636-643.
  CrossrefPubMedGoogle Scholar
• 34 Shattil SJ, Bennett JS, Colman RW. et al. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyper- betalipoproteinemia. J Lab Clin Med 1977; 89: 341-353.
  PubMedGoogle Scholar
• 35 Savi P, Zachayus JL, Delesque-Touchard N. et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 2006; 103: 11069-11074.
  CrossrefPubMedGoogle Scholar
• 36 Barlage S, Boettcher D, Boettcher A. et al. High density lipoprotein modulates platelet function. Cytometry A 2006; 69: 196-199.
  PubMedGoogle Scholar
• 37 Sattler KJ, Herrmann J, Yun S. et al. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J 2009; 30: 1894-1902.
  CrossrefPubMedGoogle Scholar
• 38 Heestermans AA, van Werkum JW, Taubert D. et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008; 122: 776-781.
  CrossrefPubMedGoogle Scholar
• 39 Fefer P, Hod H, Hammerman H. et al. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 514-518.
  CrossrefPubMedGoogle Scholar
• 40 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
  CrossrefPubMedGoogle Scholar
• 41 Zeymer U, Arntz HR, Darius H. et al. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design. Cardiology 2007; 108: 265-272.
  CrossrefPubMedGoogle Scholar
• 42 Poss J, Jacobshagen C, Ukena C. et al. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTE- MI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010; 99: 411-417.
  CrossrefPubMedGoogle Scholar
• 43 Larson DM, Duval S, Sharkey SS. et al. Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. Am Heart J 2010; 160: 202-207.
  CrossrefPubMedGoogle Scholar
• 44 Geisler T, Grass D, Bigalke B. et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
  PubMedGoogle Scholar
• 45 Michelson AD, Frelinger AL, III Braunwald E. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
  CrossrefPubMedGoogle Scholar
• 46 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
  CrossrefPubMedGoogle Scholar
• 47 Montalescot G, Wiviott SD, Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731.
  CrossrefPubMedGoogle Scholar

• Supplementary Material